Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Open Access
- 21 August 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 101 (6), 555-559
- https://doi.org/10.1002/ijc.10641
Abstract
Dedicated clinics have been established for the early diagnosis and treatment of women at risk for inherited breast cancer, but the effects of such interventions are currently unproven. This second report on prospectively diagnosed inherited breast cancer from the European collaborating centres supports the previous conclusions and adds information on genetic heterogeneity and the effect of oophorectomy. Of 249 patients, 20% had carcinoma in situ (CIS), 54% had infiltrating cancer without spread (CaN0) and 26% had cancer with spread (CaN+). Five‐year survival was 100% for CIS, 94% for CaN0 and 72% for CaN+ (p = 0.007). Thirty‐six patients had BRCA1 mutations, and 8 had BRCA2 mutations. Presence of BRCA1 mutation was associated with infiltrating cancer, high grade and lack of oestrogen receptor (p < 0.05 for all 3 characteristics). For BRCA1 mutation carriers, 5‐year survival was 63% vs. 91% for noncarriers (p = 0.04). For CaN0 patients, mutation carriers had 75% 5‐year disease‐free survival vs. 96% for noncarriers (p = 0.01). Twenty‐one of the mutation carriers had undergone prophylactic oophorectomy, prior to or within 6 months of diagnosis in 13 cases. All but 1 relapse occurred in the 15 who had kept their ovaries, (p < 0.01); no relapse occurred in those who had removed the ovaries within 6 months (p = 0.04) Contralateral cancer was more frequently observed in mutation noncarriers, but this finding did not reach statistical significance. Our findings support the concept that BRCA1 cancer is biologically different from other inherited breast cancers. While current screening protocols appear satisfactory for the majority of women at risk of familial breast cancer, this may not be the case for BRCA1 mutation carriers. The observed effect of oophorectomy was striking.This publication has 18 references indexed in Scilit:
- The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective seriesEuropean Journal of Cancer, 2001
- Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 2000
- 2157delG: a frequent mutation in BRCA2 missed by PTTJournal of Medical Genetics, 2000
- Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locusProceedings of the National Academy of Sciences of the United States of America, 2000
- Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast CancerThe New England Journal of Medicine, 1999
- Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast CancerDisease Markers, 1999
- Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast CancerDisease Markers, 1999
- Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinicsEuropean Journal of Cancer, 1998
- Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancerThe Breast, 1998
- Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1The Lancet, 1998